The Company signed a non-binding MOU with shareholders of Colugo. Colugo’s customer include the Israel Defense Forces, national first responders organizations and commercial companies Raanana, Israel, March 24, 2026 (GLOBE NEWSWIRE) — Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced the signing of a non-binding Memorandum of Understanding (“MOU”) with shareholders of Colugo Systems Ltd. (“Colugo”), an innovative Israeli developer of advanced electric Vertical Take-Off and Landing (eVTOL) drone systems, for the acquisition of up to 20% stake in Colugo. Established in 2016, Colugo designs and manufactures innovative aircraft that are designed to drive advancements in shaping aviation in the emerging Urban Air Mobility...

CRANFORD, N.J., March 24, 2026 (GLOBE NEWSWIRE) — Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”), today announced that the previously approved 1-for-100 reverse stock split will become effective on March 24, 2026, at 4:30 pm, Eastern Time (the “Effective Time”), and the Company’s common stock is expected to begin trading on a reverse stock split-adjusted basis on the OTCQB at market open on March 25, 2026. The Company’s common stock is expected to trade under the temporary symbol “ENZND” for 20 trading days.  As of the Effective Time, every one hundred (100) shares of the Company’s issued and outstanding common stock will be combined into one (1) share of common stock. The par value per share of the Company’s common stock will not change. No fractional shares will be issued in connection with the reverse stock...

Fifth Agreement between Propanc & the Universities over a 17yr PeriodJoint Research Site Visit at the Universities of Jaén and Granada, Spain, Nov 2025CEO, Mr. James Nathanielsz Along with Research Collaboration Team Members from the Universities of Jaén and Granada, Spain, at a Recent Site Visit. From Left to Right: Prof. Macarena Perán Quesada, Dr Aitor González-Titos & Dr Maria Belén Toledo (University of Jaén), Prof. Juan Antonio Marchal Corrales (University of Granada), Mr. James Nathanielsz (Propanc Biopharma Inc.)MELBOURNE, Australia, March 24, 2026 (GLOBE NEWSWIRE) — Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that a multi-year Joint...

Exclusive Dual-City Presence in Rome and Milan will Position Digital Realty as Italy’s Premier Connectivity Platform LONDON, March 24, 2026 (GLOBE NEWSWIRE) — Digital Realty (NYSE: DLR), the world’s largest cloud- and carrier-neutral data center platform, today announced its coming entry into the Milan market, marking a significant expansion in one of Europe’s most economically powerful and digitally dynamic regions. Digital Realty’s expansion into Milan strengthens its leadership in digital infrastructure across the Mediterranean and Southern Europe, connecting key hubs in Athens, Marseille, and Sofia, with new sites underway in Barcelona, Crete, and other key markets. Positioned at the crossroads of Europe, Africa, the Middle East, and Asia, this region is emerging as a vital digital interconnection point, and Digital Realty remains...

Ra’anana, Israel, March 24, 2026 (GLOBE NEWSWIRE) — Rail Vision Ltd. (Nasdaq: RVSN, FSE: C80) (“Rail Vision” or the “Company”), an early commercialization stage technology company transforming railway safety through advanced AI-integrated sensing systems, today announced that its ordinary shares have begun trading on the Frankfurt Stock Exchange (“FSE”), under the symbol C80. The Company’s ordinary shares will continue to trade on the Nasdaq Capital Market, under the symbols “RVSN”. The FSE, operated by Deutsche Börse AG, is among the world’s largest and most prestigious securities trading venues, featuring expanded access to European institutional and retail investors. The Company believes that the availability of trading on the FSE may enhance its visibility and trading liquidity in Europe, which may broaden the Company’s investor...

A new system with intelligent robotic arm picking, decoupled architecture, and zero-shot learning STUTTGART, Germany, March 24, 2026 (GLOBE NEWSWIRE) — Geekplus (HKEX: 2590.HK), a global leader in autonomous mobile robotics, introduces RoboShuttle V5, a major upgrade to its tote-to-person and embedded robot arm picking station solution. RoboShuttle V5 sets a new industry standard for fully autonomous picking and warehouse fulfillment. The system debuts at LogiMAT 2026 in Stuttgart, Germany (March 24-26). Most tote-to-person systems on the market today automate storage and retrieval but still depend on human pickers at the workstation, creating a persistent bottleneck that limits 24/7 throughput. By integrating its Robot Arm Picking Station natively into the platform, Geekplus bridges the gap where manual labor reaches its limit,...

Significant regulatory milestone marks advancement into clinical-stage development of next-generation RNAi therapy featuring an innovative, integrated systemic treatment delivery approach targeting highly prevalent KRAS-driven cancers with significant unmet medical need Company reported strong positive preclinical study results demonstrating significant anti-tumor activity in multiple models and announced successful completion of toxicology studies, and constructive regulatory engagement supporting the Phase 2/3 trial design Silexion expects to initiate human clinical trials in the second quarter of 2026 Grand Cayman, Cayman Islands, March 24, 2026 (GLOBE NEWSWIRE) — Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced...

The clinically proven formula pairs NAD+ with its precursors to replenish skin cells and address nine signs of skin aging for healthier, more resilient-looking skinNEW YORK, March 24, 2026 (GLOBE NEWSWIRE) — Obagi Medical (“Obagi”), a leader in advanced skincare innovation, the originator of medical-grade skincare and part of Waldencast plc (NASDAQ: WALD) (“Waldencast” or the “Company”), is proud to announce the latest innovation in advanced skin science and longevity with the launch of its newest breakthrough: Obagi NU-GEN™ Cellular Renewal Serum. A cellular renewal serum that acts like a power supply for your skin and supports its natural cellular functions. The formula is clinically proven to visibly rewind skin’s age by up to six years1 by helping replenish skin cells with NAD+ and addressing nine signs of skin aging...

MIAMI, March 24, 2026 (GLOBE NEWSWIRE) — Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic holding company focused on a diversified healthcare portfolio, today announced the official launch of MyOnlineConsultation.com through MOCTeledoc, LLC, a fully integrated doctor network delivering both technology and clinical staffing solutions to digital health companies. Following its beta phase, MOCTeledoc launches with an established cash-flow-positive status, validating the division’s lean business model. Financial and Strategic HighlightsRevenue Growth Strategy: Management projects MOCTeledoc will become a significant revenue stream alongside the Company’s compounding and direct-to-consumer divisions, which generated $25.9 million in revenue for the nine months ended December 31, 2025. Vertical...

Inflammatory Biomarker Tracking Predicted to Enhance  Response to 3-D Bio-Printed Therapies Expands OneTest for Longevity with Chronic Kidney Disease Risk Assessment GAITHERSBURG, Md., March 24, 2026 (GLOBE NEWSWIRE) — 20/20 BioLabs, Inc. (“20/20”), 20/20 BioLabs (Nasdaq: AIDX), an early market entrant in cutting-edge, AI powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it has entered into an exclusive U.S. technology license and access agreement with ROKIT Healthcare Inc. (“ROKIT”), a global innovator in chronic disease prediction and regenerative health technologies. Under the agreement, 20/20 will integrate ROKIT’s proprietary chronic kidney disease (CKD) prediction algorithm into the 20/20 Longevity Platform, expanding its suite of biomarker-based...